An analysis of 10 years of clinical trials shows no improvement in diversity over time, even though the U.S. Food and Drug Administration established recommendations for increasing diversity in 1993. This is even more harmful because we now know that gender, race and ethnicity can affect responses to medications and require tailored treatments. In the clinical trials reviewed between 2008 and 2017, only 36% of participants were women, 4% were Black or African American, 12% were Asian and 11% were Hispanic/Latino. Women were particularly underrepresented in clinical trials for heart disease, heart failure and acute coronary syndrome compared to the proportion of women in the population who have these diseases. In the United States, the Go Red for Women initiative has helped create a community of women scientists, researchers, and medical and health professionals to close these gender disparities. Our goal at Women’s Cardiovascular Healthcare Foundation (Agir pour le Cœur des Femmes) is to create a similar initiative in France. https://newsroom.heart.org/news/women-and-minorities-lacking-in-research-and-clinical-trials-for-new-cardiometabolic-medications
This is unacceptable: not only do fewer than one in two women have a mammogram for breast cancer screening, but these figures are also falling: 46.5% of women aged 50 to 74 had a mammogram in 2023, compared with 47.6% in 2022! Yet 9 out of 10 breast cancers can be cured when detected at an early [...]
If we manage to be optimistic, we'll live longer. And probably happier. The life expectancy of the most optimistic is 5% higher than that of the most pessimistic, an average of just over four years. These are the conclusions of a vast study conducted by the American Geriatrics Society on the [...]